Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Abeona Therapeutics Inc (ABEO) vs AGCO Corporation (AGCO) Price & Performance

Abeona Therapeutics IncTrade
AGCO CorporationTrade

Price performance (Past 24H)

Key statistics

Abeona Therapeutics Inc vs AGCO Corporation — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $421.19M), while AGCO Corporation trades at $101.37 (market cap $7.10B). The key difference: AGCO Corporation is far larger — about 16.9× Abeona Therapeutics Inc's market cap, and AGCO Corporation pays a 1.18% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.

ABEOAGCO
Market Cap
$421.19M$7.10B
Sector
HealthIndustrials
52-Week High
$7.45$140.49
52-Week Low
$4.17$100.14
Enterprise Value
$276.10M$9.37B
Dividend Yield
1.18%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Abeona Therapeutics Inc

ABEO trades at $7.46, up 0.13% with strong technical momentum as moving averages signal bullish sentiment. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent positive developments include CMS granting NTAP status for ZEVASKYN and expanding treatment centers, while consistently beating earnings expectations.

Outlook remains positive with analyst consensus at 66.7% buy ratings, but risks include shareholder investigation and high RSI levels suggesting overbought conditions. The stock's valuation appears reasonable with P/E of 7.78, though negative operating cash flow requires monitoring as the company scales commercialization efforts.

AGCO Corporation

AGCO trades at $101.55, up 0.67% on the day, with a bearish technical signal and mixed fundamentals. Recent Q2 2026 earnings missed estimates, leading to an 11% share drop and multiple legal investigations. The company maintains a solid balance sheet with $612M cash and a 5.15% net income margin, but faces headwinds from lowered 2026 guidance and weak agricultural demand.

The outlook is cautious; while valuation ratios like P/E of 14.03 appear attractive and analysts set a $124.63 consensus target, risks from earnings volatility, legal scrutiny, and industry softness outweigh near-term opportunities. Investors should weigh the dividend yield against potential further downside from ongoing investigations and macroeconomic pressures.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Abeona Therapeutics Inc

Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.

Read more on ABEO

About AGCO Corporation

Agco is a global manufacturer of agricultural equipment. The company has five principal brands: Fendt, Massey Ferguson, Challenger, Valtra, and GSI. Unlike its competitors, Agco's product line extends beyond self-propelled equipment and implements by offering grain handling systems and livestock management solutions. Its products are available through a global dealer network, which includes over 3,200 dealer and distribution locations. Additionally, Agco offers both retail and wholesale financing to customers through its joint venture with Rabobank, a European food and agriculture focused bank.

Read more on AGCO